Company profile: Theraclion
1.1 - Company Overview
Company description
- Provider of high-intensity focused ultrasound (HIFU) echotherapy medical equipment, combining HIFU with standard ultrasound for non-invasive treatment and target localization. Solutions include SONOVEIN for varicose veins; ECHOPULSE for thyroid nodules and breast fibroadenoma; CURE-OP for combinational cancer therapy integrating ultrasound with radiotherapy; and EPack single-use disposables for cooling and coupling.
Products and services
- CURE-OP: Modular HIFU platform for combinational cancer therapy, integrating ultrasound with radiotherapy to enhance treatment efficacy and safety
- ECHOPULSE: Clinical-grade non-invasive echotherapy system treating thyroid nodules and breast fibroadenoma using high-intensity focused ultrasound combined with standard ultrasound for precise targeting
- Employs EPack for cooling and coupling
- SONOVEIN: Industrial-grade non-invasive echotherapy system for varicose veins, using high-intensity focused ultrasound combined with standard ultrasound for accurate target localization
- Utilizes EPack to maintain cooling and coupling during treatments
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Theraclion
Molecular Templates
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for cancer and other serious diseases, leveraging a proprietary engineered toxin body (ETB) platform with unique mechanisms of action. Pipeline includes MT-6402 (PD-L1), MT-8421 (CTLA-4), and MT-0169 (CD38). Operates a multi-product cGMP manufacturing facility in Austin, TX to supply clinical trial materials for internal and partnered ETB programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Molecular Templates company profile →
Koya Medical
HQ: United States
Website
- Description: Provider of breakthrough treatments for lymphedema and venous diseases, as a transformative healthcare company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Koya Medical company profile →
MirImmune Bio
HQ: United States
Website
- Description: Provider of biopharmaceutical R&D focused on new and improved cancer immunotherapies, combining immune checkpoint inhibition and cell-based immunotherapies, aiming to achieve long-term survival of cancer patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MirImmune Bio company profile →
WntResearch
HQ: Sweden
Website
- Description: Provider of anti-metastatic cancer therapies targeting WNT5A signaling. Pipeline includes Foxy-5, a peptide drug candidate that mimics WNT5A to reduce cancer cell mobility and spread (Phase I; reconstitutes Wnt-5a effects in breast cancer cells), and Box-5, a peptide in preclinical development that antagonizes Wnt-5a.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full WntResearch company profile →
Favrille
HQ: United States
Website
- Description: Provider of targeted immunotherapies, focused on research, development and commercialization for the treatment of cancer and other diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Favrille company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Theraclion
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Theraclion
2.2 - Growth funds investing in similar companies to Theraclion
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Theraclion
4.2 - Public trading comparable groups for Theraclion
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →